Human acellular dermal matrix for middle hepatic vein reconstruction in living donor liver transplantation: a prospective feasibility and safety study

Background: During living donor liver transplantation (LDLT), middle hepatic vein (MHV) reconstruction requires a conduit that preserves early venous outflow while avoiding late device-related complications typical of synthetic grafts. We evaluated human acellular dermal matrix (ADM) as an off-the-shelf biological conduit. Methods: In a prospective single-center cohort (2022–2025), adults undergoing LDLT with MHV reconstruction using ADM ( n = 40) were followed. Outcomes were benchmarked against historical controls using Hemashield ( n = 40) or polytetrafluoroethylene (PTFE; n = 20). Primary endpoints were early-phase patency (≤6 months) and major structural complications. Two blinded radiologists independently reviewed serial Doppler ultrasonography and contrast-enhanced computed tomography with consensus adjudication. Patency was estimated by Kaplan–Meier and compared with the log-rank test. Results: ADM achieved excellent early patency [95.0% (83.5–98.6) at 3 months; 85.0% (70.9–92.9) at 6 months]. At 18 months, patency was 62.5% for ADM versus 50.0% (PTFE) and 47.5% (Hemashield) (log-rank P = 0.785). No ADM graft required re-intervention, and no graft infection or duodenal invasion occurred (0/40 vs 2/60 [3.3%] in synthetic cohorts). Baseline characteristics were comparable. Case review showed that several ADM occlusions were associated with large bilomas, where secondary infection rather than intrinsic graft failure likely triggered thrombosis. Conclusions: ADM is a feasible and safe biological conduit for MHV reconstruction, delivering robust patency throughout the critical period of graft regeneration while avoiding catastrophic complications observed with synthetic materials. These hypothesis-generating results support a randomized trial and introduce the concept of ADM as a temporary biological scaffold. Given its excellent early patency and safety profile, ADM should be considered a valuable addition to the surgical armamentarium with potential to redefine success in venous reconstruction.

Authors

Institutions

Publication Details

Journal
International Journal of Surgery
Published
2026-04-16
DOI
https://doi.org/10.1097/js9.0000000000005143
Primary Topic
Organ Transplantation Techniques and Outcomes
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Human acellular dermal matrix for middle hepatic vein reconstruction in living donor liver transplantation: a prospective feasibility and safety study

In‐Sang Song, Min‐Kyung Yeo, Seok‐Hwan Kim, Sunjong Han et al.
International Journal of Surgery
Organ Transplantation Techniques and Outcomes
article

Human acellular dermal matrix for middle hepatic vein reconstruction in living donor liver transplantation: a prospective feasibility and safety study

In‐Sang Song, Min‐Kyung Yeo, Seok‐Hwan Kim, Sunjong Han, Gwang-Sik Chun, Hyuk-Soo Eun
article en

Abstract

Background: During living donor liver transplantation (LDLT), middle hepatic vein (MHV) reconstruction requires a conduit that preserves early venous outflow while avoiding late device-related complications typical of synthetic grafts. We evaluated human acellular dermal matrix (ADM) as an off-the-shelf biological conduit. Methods: In a prospective single-center cohort (2022–2025), adults undergoing LDLT with MHV reconstruction using ADM ( n = 40) were followed. Outcomes were benchmarked against historical controls using Hemashield ( n = 40) or polytetrafluoroethylene (PTFE; n = 20). Primary endpoints were early-phase patency (≤6 months) and major structural complications. Two blinded radiologists independently reviewed serial Doppler ultrasonography and contrast-enhanced computed tomography with consensus adjudication. Patency was estimated by Kaplan–Meier and compared with the log-rank test. Results: ADM achieved excellent early patency [95.0% (83.5–98.6) at 3 months; 85.0% (70.9–92.9) at 6 months]. At 18 months, patency was 62.5% for ADM versus 50.0% (PTFE) and 47.5% (Hemashield) (log-rank P = 0.785). No ADM graft required re-intervention, and no graft infection or duodenal invasion occurred (0/40 vs 2/60 [3.3%] in synthetic cohorts). Baseline characteristics were comparable. Case review showed that several ADM occlusions were associated with large bilomas, where secondary infection rather than intrinsic graft failure likely triggered thrombosis. Conclusions: ADM is a feasible and safe biological conduit for MHV reconstruction, delivering robust patency throughout the critical period of graft regeneration while avoiding catastrophic complications observed with synthetic materials. These hypothesis-generating results support a randomized trial and introduce the concept of ADM as a temporary biological scaffold. Given its excellent early patency and safety profile, ADM should be considered a valuable addition to the surgical armamentarium with potential to redefine success in venous reconstruction.

International Journal of Surgery
Chungnam National University (KR), Chungnam National University Hospital (KR)
Good health and well-being
Openalex Percentile: Top 16%
Organ Transplantation Techniques and Outcomes
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.